• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

曲坦类药物与选择性 5-羟色胺再摄取抑制剂/5-羟色胺去甲肾上腺素再摄取抑制剂联合应用后出现一过性悲伤:病例报告。

Onset of Transient Sadness Following the Concomitant Use of a Triptan and Selective Serotonin Reuptake Inhibitor/Serotonin Norepinephrine Reuptake Inhibitors Therapy: A Case Report.

机构信息

Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.

出版信息

J Pharm Pract. 2023 Jun;36(3):705-710. doi: 10.1177/08971900211064444. Epub 2021 Dec 28.

DOI:10.1177/08971900211064444
PMID:34962845
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10189819/
Abstract

Migraine and depression have a bi-directional, positive association. The likelihood of these conditions being comorbidities is high, thus, the possibility of concomitant use of an antidepressant and a triptan is also increased. We present a case of a 39-year-old female with a history of migraine with aura and depression who had brief episodes of exacerbated depressive symptoms following oral administration of sumatriptan 100 mg daily as needed while taking various selective serotonin reuptake inhibitor (SSRI) and serotonin and norepinephrine reuptake inhibitor (SNRI) medications on different occasions. The patient experienced 30-minute episodes of sweating and subjective increase in temperature approximately 2-3 hours after administration of sumatriptan 100 mg. This was followed by a transient exacerbation of sadness described by the patient as unhappiness, hopelessness, and tearfulness, which lasted 1 to 2 hours. To date, there are no other published case reports that have described this particular presentation. Several studies have reported possible serotonin syndrome as a result of the combination. Current evidence and known pharmacological actions of SSRIs/SNRIs and triptans are not well-defined enough to explain how one can experience episodic worsening depression. This case illustrates that clinicians should consider other potential adverse effects of the combined use of triptans and SSRIs/SNRIs beyond serotonin syndrome.

摘要

偏头痛和抑郁症之间存在双向正相关关系。这些病症同时存在的可能性很高,因此,同时使用抗抑郁药和曲坦类药物的可能性也增加了。我们报告了一例 39 岁女性病例,她有先兆偏头痛和抑郁症病史,在不同情况下服用各种选择性 5-羟色胺再摄取抑制剂(SSRI)和 5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRI)药物时,每日按需口服舒马曲坦 100 毫克后,短暂出现抑郁症状加重。在服用舒马曲坦 100 毫克后约 2-3 小时,患者会出现 30 分钟的出汗和主观体温升高,随后出现短暂的悲伤加重,患者描述为不快乐、绝望和流泪,持续 1 至 2 小时。迄今为止,尚无其他已发表的病例报告描述这种特殊表现。一些研究报告了可能的血清素综合征是由于联合用药引起的。目前的证据和已知的 SSRI/SNRI 和曲坦类药物的药理学作用还不够明确,无法解释为什么会出现间歇性恶化的抑郁。这个病例说明,临床医生应该考虑到曲坦类药物和 SSRI/SNRI 联合使用除了血清素综合征以外的其他潜在不良反应。

相似文献

1
Onset of Transient Sadness Following the Concomitant Use of a Triptan and Selective Serotonin Reuptake Inhibitor/Serotonin Norepinephrine Reuptake Inhibitors Therapy: A Case Report.曲坦类药物与选择性 5-羟色胺再摄取抑制剂/5-羟色胺去甲肾上腺素再摄取抑制剂联合应用后出现一过性悲伤:病例报告。
J Pharm Pract. 2023 Jun;36(3):705-710. doi: 10.1177/08971900211064444. Epub 2021 Dec 28.
2
Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome.曲坦类抗偏头痛药物与选择性 5-羟色胺再摄取抑制剂或选择性去甲肾上腺素再摄取抑制剂抗抑郁药联合使用与血清素综合征相关。
JAMA Neurol. 2018 May 1;75(5):566-572. doi: 10.1001/jamaneurol.2017.5144.
3
The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.美国食品药品监督管理局关于曲坦类药物与选择性 5-羟色胺再摄取抑制剂或选择性 5-羟色胺-去甲肾上腺素再摄取抑制剂联合使用引发 5-羟色胺综合征的警示:美国头痛协会立场文件。
Headache. 2010 Jun;50(6):1089-99. doi: 10.1111/j.1526-4610.2010.01691.x.
4
The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reports.美国食品药品监督管理局关于5-羟色胺综合征与选择性5-羟色胺再摄取抑制剂(SSRI)或5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI)及曲普坦类药物联合使用的警示:对29例病例报告的分析
MedGenMed. 2007 Sep 5;9(3):48.
5
Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome.美国食品和药物管理局发出关于血清素综合征的警告后,曲坦类药物与 SSRI 或 SNRI 同时使用。
Headache. 2012 Feb;52(2):198-203. doi: 10.1111/j.1526-4610.2011.02067.x. Epub 2012 Jan 30.
6
Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome.曲坦类药物与5-羟色胺再摄取抑制剂(SSRI)或5-羟色胺去甲肾上腺素再摄取抑制剂(SNRI)联合使用:5-羟色胺综合征的风险。
Headache. 2008 Jan;48(1):126-9. doi: 10.1111/j.1526-4610.2007.00964.x. Epub 2007 Nov 13.
7
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.选择性5-羟色胺再摄取抑制剂(SSRIs)和5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRIs)用于预防成人偏头痛。
Cochrane Database Syst Rev. 2015 Apr 1;4(4):CD002919. doi: 10.1002/14651858.CD002919.pub3.
8
Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted?选择性5-羟色胺再摄取抑制剂/5-羟色胺-去甲肾上腺素再摄取抑制剂(SSRI/SNRI)类药物与曲坦类药物联用时的血清素综合征风险:美国食品药品监督管理局(FDA)的警示是否合理?
Ann Pharmacother. 2008 Nov;42(11):1692-6. doi: 10.1345/aph.1L260. Epub 2008 Oct 28.
9
Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis.选择性 5-羟色胺再摄取抑制剂和选择性 5-羟色胺和去甲肾上腺素再摄取抑制剂的使用与成年人骨折风险:系统评价和荟萃分析。
Int J Geriatr Psychiatry. 2018 Dec;33(12):1688-1708. doi: 10.1002/gps.4974. Epub 2018 Sep 24.
10
Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older.血清素-去甲肾上腺素再摄取抑制剂和选择性血清素再摄取抑制剂的使用与骨折风险:一项针对美国50岁及以上成年人的新用户队列研究。
CNS Drugs. 2015 Mar;29(3):245-52. doi: 10.1007/s40263-015-0231-5.

本文引用的文献

1
Demystifying serotonin syndrome (or ).揭开血清素综合征(或 5-HT 综合征)的神秘面纱。
Can Fam Physician. 2018 Oct;64(10):720-727.
2
The scoop on serotonin syndrome.血清素综合征的详情。
Can Pharm J (Ott). 2018 May 30;151(4):233-239. doi: 10.1177/1715163518779096. eCollection 2018 Jul-Aug.
3
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.加拿大情绪与焦虑治疗网络(CANMAT)2016年成人重度抑郁症管理临床指南:第3节. 药物治疗。
Can J Psychiatry. 2016 Sep;61(9):540-60. doi: 10.1177/0706743716659417. Epub 2016 Aug 2.
4
5-HT1B receptor modulation of the serotonin transporter in vivo: studies using KO mice.体内5-羟色胺转运体的5-羟色胺1B受体调节:使用基因敲除小鼠的研究
Neurochem Int. 2014 Jul;73:127-31. doi: 10.1016/j.neuint.2013.11.004. Epub 2013 Nov 15.
5
Canadian Headache Society Guideline: acute drug therapy for migraine headache.加拿大头痛学会指南:偏头痛急性药物治疗。
Can J Neurol Sci. 2013 Sep;40(5 Suppl 3):S1-S80.
6
Drug interactions with triptans : which are clinically significant?与曲坦类药物的相互作用:哪些具有临床意义?
CNS Drugs. 2012 Nov;26(11):949-57. doi: 10.1007/s40263-012-0002-5.
7
Possible association of severe major depression with acute cessation of long-term excessive triptan use.可能与长期过量使用曲坦类药物突然停药有关的严重复发性抑郁症。
J Clin Pharm Ther. 2013 Feb;38(1):77-9. doi: 10.1111/jcpt.12009. Epub 2012 Sep 27.
8
5-HT(1B) autoreceptor regulation of serotonin transporter activity in synaptosomes.5-HT(1B) 自身受体对突触体中 5-羟色胺转运体活性的调节。
Synapse. 2012 Dec;66(12):1024-34. doi: 10.1002/syn.21608. Epub 2012 Sep 29.
9
Canadian Headache Society guideline for migraine prophylaxis.加拿大头痛学会偏头痛预防指南。
Can J Neurol Sci. 2012 Mar;39(2 Suppl 2):S1-59.
10
Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome.美国食品和药物管理局发出关于血清素综合征的警告后,曲坦类药物与 SSRI 或 SNRI 同时使用。
Headache. 2012 Feb;52(2):198-203. doi: 10.1111/j.1526-4610.2011.02067.x. Epub 2012 Jan 30.